AACR 2024 | Clinical advances in brain cancer: AZD1390 and CAR-T cells in glioma

Patrick Wen, MD, Dana-Farber Cancer Institute, Boston, MA, highlights recent clinical advances in brain cancer. There is increasing interest in targeting DNA damage response, with research in other cancers looking at ATM and ATR inhibitors. AZD1390 is an ATM inhibitor able to penetrate the blood brain barrier, potentially enabling its use to treat brain tumors. A Phase I study (NCT03423628) demonstrates good tolerability and therapeutic potential. Research into the use of GD2-directed CAR-T cells suggest it may have activity in diffuse midline gliomas, however responses do not yet appear durable. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.